Inhibin A is a placental and ovarian protein measured in maternal blood as one part of the second-trimester quad screen. The laboratory combines inhibin A with alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), unconjugated estriol, maternal age, gestational age, weight, and other pregnancy details to estimate the chance of trisomy 21 and trisomy 18. An elevated inhibin A level contributes to the typical trisomy 21 screening pattern, especially when hCG is high and AFP and estriol are low. The marker is usually reported as a multiple of the median, or MoM, rather than interpreted from its raw concentration. High inhibin A does not diagnose Down syndrome, and an isolated result cannot determine whether a fetus is affected. It may also be associated with placental complications in some pregnancies, but the value is not specific enough to predict them by itself. Accurate dating and a complete risk report are essential before deciding whether follow-up should include genetic counseling, cell-free DNA screening, detailed ultrasound, or diagnostic amniocentesis.
- Inhibin A is one of four maternal serum markers in the second-trimester quad screen.
- Testing is usually offered from 15 to 22 weeks, with many programs preferring 16 to 18 weeks.
- Elevated inhibin A contributes to a higher calculated risk for trisomy 21 but is not diagnostic.
- Results are converted to MoM and adjusted for gestational age, weight, diabetes, and other factors.
- A screen-positive result should be followed by counseling and a choice of further screening or diagnostic testing.
Table of Contents
- What Inhibin A Is
- Inhibin A in the Quad Screen
- Timing, Preparation, and Adjustments
- Understanding MoM and Risk Results
- High Inhibin A Results
- Low or Normal Inhibin A Results
- Follow-Up After a Positive Quad Screen
- Placental Associations and Limitations
What Inhibin A Is
Inhibins are protein hormones in the transforming growth factor beta family. Inhibin A consists of an alpha subunit linked to a beta-A subunit. Outside pregnancy, the ovaries produce inhibin A, and clinicians may use related measurements in fertility or ovarian evaluation. During pregnancy, the corpus luteum contributes early, while the placenta and decidual tissues become important sources.
Maternal inhibin A rises early, changes across the first and second trimesters, and increases again toward term. Because its concentration varies with gestational age, the raw number cannot be interpreted against one fixed pregnancy range. Prenatal laboratories compare the concentration with a gestational-age median and report a corrected MoM.
The hormone participates in local signaling involving activin, follistatin, gonadotropins, and placental steroid production. Its exact roles in placental development and fetal growth are complex. For screening purposes, however, the important fact is epidemiologic: pregnancies affected by trisomy 21 tend to have higher maternal inhibin A in the second trimester than unaffected pregnancies.
Inhibin A does not come directly from the fetal chromosomes, nor does it measure fetal intelligence, anatomy, or current well-being. It is a biochemical marker whose distribution differs between groups. The distributions overlap widely, which prevents the marker from serving as a stand-alone Down syndrome test.
A laboratory may list “DIA,” meaning dimeric inhibin A. That is the biologically active form used in the quad screen. It should not be confused with inhibin B, which has different patterns and uses. It is also separate from the PAPP-A marker used in first-trimester screening.
When an inhibin A result appears in a patient portal before the full panel is complete, it can be tempting to interpret the flag alone. The final combined risk is the clinically meaningful product. A laboratory flag based on its analyte interval is not the same as a screen-positive trisomy result.
Inhibin A in the Quad Screen
The quad screen measures four substances in maternal blood:
- AFP: a fetal protein that enters maternal circulation through the placenta;
- hCG: a placental hormone;
- unconjugated estriol (uE3): an estrogen made through cooperation among the fetus, placenta, and maternal body;
- inhibin A: a hormone produced largely by placental tissues during pregnancy.
The algorithm combines these markers with maternal age and other clinical data. The classic trisomy 21 pattern is lower AFP, higher hCG, lower uE3, and higher inhibin A. The trisomy 18 pattern more often includes low AFP, low hCG, and low uE3; inhibin A is not typically the dominant contributor. AFP also screens for open neural tube and abdominal-wall defects, which inhibin A does not.
| Condition screened | Common marker pattern | Role of inhibin A |
|---|---|---|
| Trisomy 21 | AFP low, hCG high, uE3 low, inhibin A high | Adds independent risk information |
| Trisomy 18 | AFP low, hCG low, uE3 low | Often normal or less informative |
| Open neural tube defect | AFP high | Inhibin A does not detect the defect |
| Unaffected pregnancy | Broad overlapping values | May still be high or low by chance |
Adding inhibin A to the older triple screen improves detection of trisomy 21 at a similar false-positive rate. Performance depends on population, cutoffs, dating accuracy, and whether the quad screen is used alone or as part of an integrated or sequential strategy.
The quad screen is a screen, not a diagnostic chromosome test. A screen-positive result identifies a group with increased probability. Most screen-positive pregnancies do not ultimately have trisomy 21, especially when the patient’s starting probability is low. The report’s positive predictive value depends on age, prevalence, and the exact marker pattern.
Cell-free DNA has higher screening accuracy for trisomy 21, 18, and 13. Even so, the quad screen remains useful when prenatal care begins after the first trimester, cell-free DNA is unavailable or declined, or second-trimester serum screening is part of a planned integrated pathway. Its AFP component also provides information about open fetal defects.
Timing, Preparation, and Adjustments
The usual quad-screen window is 15 weeks through 22 weeks of gestation. Many programs prefer collection around 16 to 18 weeks because marker medians and follow-up timing are well established. The exact laboratory window controls whether a sample can be accepted.
No fasting is normally required. The test uses a venous blood sample. Food, routine prenatal vitamins, and ordinary exercise do not meaningfully change inhibin A for screening purposes. If other fasting tests are ordered at the same visit, follow those separate instructions.
Accurate clinical information is more important than special preparation. Before the sample is processed, verify:
- estimated due date and the method used to establish it;
- maternal weight on or near the collection date;
- singleton, twin, or higher-order gestation;
- insulin-treated diabetes, if requested by the program;
- smoking status and demographic factors used by the laboratory;
- in vitro fertilization, donor egg, and other assisted-conception details;
- a known fetal loss in a multiple pregnancy;
- whether first-trimester screening was already performed as part of an integrated plan.
Gestational dating errors can shift all four MoMs in a recognizable direction. If ultrasound later changes the due date, the clinician may request recalculation. The laboratory usually needs the revised gestational age and may have limits on how much or how late it can revise the report. Repeating the blood draw is not always necessary.
Maternal weight affects serum-marker concentration through blood-volume dilution. Higher weight generally lowers measured concentrations, so the software applies a correction. Multiple pregnancy increases marker production and requires a separate algorithm. Donor-egg pregnancies may require donor age for the prior chromosome risk, depending on the program.
Results commonly take several days. A complete report should identify the gestational age used, adjusted MoMs, condition-specific risk estimates, and the screening cutoff. If only the inhibin A concentration appears, wait for the completed calculation or contact the ordering office rather than drawing conclusions from a single flagged value.
Understanding MoM and Risk Results
MoM means multiple of the median. An inhibin A result of 1.0 MoM equals the median for pregnancies at the same gestational age in the laboratory’s reference population. A value of 2.0 MoM is twice that median. Corrected MoM incorporates the patient-specific factors used by the program.
Inhibin A around 2.0 MoM or higher is often described as elevated in screening literature, but no universal threshold diagnoses trisomy 21. The algorithm treats risk as continuous. A value of 1.9 MoM and 2.1 MoM are biologically similar even if one receives a flag.
The final report may show a probability such as 1 in 120 or 1 in 3,000. A 1-in-120 result means that among pregnancies with the same calculated profile, approximately one would be expected to have the condition and 119 would not. It is about 0.83%, not 120% and not a diagnosis. A 1-in-3,000 probability is approximately 0.03%.
Screen-positive cutoffs vary. A laboratory might use 1 in 270 for trisomy 21, while another program uses a nearby threshold. A result of 1 in 200 would be positive under either; 1 in 500 might be negative. Ask for the actual number rather than relying only on “positive” or “negative.”
The same inhibin A MoM can produce different final risks because:
- maternal age changes the starting probability;
- the other three markers may reinforce or offset the pattern;
- gestational age and adjustments change the corrected MoM;
- ultrasound findings may influence counseling even if they are not included in the algorithm;
- the program may integrate first-trimester results.
A negative quad screen lowers the probability of the screened conditions but cannot exclude them. It also does not screen for every chromosome change, single-gene disorder, structural anomaly, autism, or developmental difference. A second-trimester anatomy scan remains recommended regardless of the serum result.
High Inhibin A Results
High inhibin A contributes to an increased trisomy 21 risk when it appears with the rest of the characteristic quad-screen pattern. The stronger and more internally consistent the pattern, the more it may shift the calculation. Yet many unaffected pregnancies have inhibin A above 2.0 MoM, and some trisomy 21 pregnancies do not.
Reasons for an elevated value include:
- normal placental and biological variation;
- incorrect gestational age or maternal weight;
- a multiple pregnancy not entered correctly;
- a trisomy 21-associated marker pattern;
- placental variation associated with preeclampsia, fetal growth restriction, preterm birth, or stillbirth in some studies;
- assay variation or a data-entry error.
The first response should be to review the complete report and its inputs. If the due date is wrong, the clinician can ask the laboratory whether recalculation is appropriate. If twins were missed on the requisition, the singleton algorithm is invalid.
An isolated high result with a low-risk final chromosome screen does not diagnose placental insufficiency. Studies have found group-level associations between high inhibin A and later obstetric complications, particularly when levels are markedly elevated or other markers are abnormal. The association may reflect placental stress or altered trophoblast function. It cannot tell whether an individual fetus is currently compromised.
Depending on the degree of elevation, other risk factors, and local guidance, the obstetric clinician may consider a detailed anatomy scan, serial fetal-growth ultrasound, or later antenatal surveillance. The schedule should be individualized; testing every patient with a mildly high isolated result can create false alarms without improving outcomes.
There is no diet, supplement, or medicine used to lower inhibin A. Treatment is directed toward an identified condition, such as managing hypertension, monitoring fetal growth, or evaluating a positive aneuploidy screen. Restricting activity or food based only on the marker is not evidence based.
Low or Normal Inhibin A Results
A low inhibin A value is generally less important for trisomy 21 screening than a high value. It may contribute modestly to the calculation depending on the assay and algorithm, but it does not have a widely used stand-alone low threshold.
A normal inhibin A result cannot cancel abnormalities in the other markers. For example, a markedly high AFP still requires evaluation for dating error, multiple gestation, fetal open defects, bleeding, or placental causes even when inhibin A is near 1.0 MoM. Similarly, low AFP, low uE3, and low hCG may produce an elevated trisomy 18 risk despite normal inhibin A.
Normal inhibin A also does not rule out Down syndrome. Screening sensitivity is less than 100%, and affected and unaffected marker distributions overlap. The correct interpretation is that the value contributes less evidence toward the high-inhibin pattern—not that chromosome status is known.
Low values can reflect:
- normal variation;
- a gestational-age or correction-factor issue;
- assay-specific distribution;
- placental or ovarian biology without a defined clinical consequence.
When the overall quad screen is low risk, routine prenatal care continues, including the anatomy ultrasound and any recommended AFP interpretation. Additional aneuploidy screening is not usually added solely for reassurance, because overlapping screens can create discordant results. A patient may still choose diagnostic testing after counseling, since diagnostic options are available regardless of age or screening category.
If ultrasound later identifies an anomaly or enlarged nuchal fold, the earlier low-risk screen does not end the evaluation. The residual risk, finding-specific differential diagnosis, cell-free DNA status, and diagnostic testing options should be reviewed again.
Follow-Up After a Positive Quad Screen
A positive quad screen should lead to an organized discussion, not a conclusion that the fetus is affected. Verify the due date, fetus number, and patient information before choosing the next test.
Follow-up options often include:
- Genetic counseling. The counselor explains the exact risk, test limitations, family history, and differences between screening and diagnosis.
- Detailed ultrasound. A targeted anatomy examination may find structural anomalies or soft markers. A normal scan reduces concern for some conditions but cannot exclude trisomy 21.
- Cell-free DNA screening. This blood test has better performance for common trisomies. It can be used as a secondary screen when a patient wants to avoid an invasive procedure, but a low-risk result does not explain every abnormal quad marker and delays certainty.
- Amniocentesis. Usually performed at or after 15 weeks, amniocentesis obtains fetal cells from amniotic fluid for diagnostic chromosome testing. It can provide a definitive answer for the tested conditions.
- AFP-focused evaluation. If high AFP drove the positive screen, targeted ultrasound and sometimes amniotic-fluid testing may be more relevant than cell-free DNA because cell-free DNA does not screen for open neural tube defects.
The best next step depends on which condition was flagged. A trisomy 21 risk driven by high inhibin A and hCG leads to a different conversation from a high open-neural-tube-defect risk driven by AFP.
No irreversible pregnancy decision should be based on inhibin A or the quad screen alone. Diagnostic confirmation is appropriate when a definitive chromosome answer is needed. Patients may also decline further testing after understanding residual uncertainty.
A positive screen can cause intense anxiety. Ask the clinician to translate the risk into a percentage and explain how many screen-positive pregnancies are unaffected. Knowing the exact probability and testing choices makes the result more manageable than focusing on red flags in the portal.
Placental Associations and Limitations
Inhibin A is produced by placental tissues, so researchers have studied it as a marker of placental dysfunction. Elevated second-trimester values have been associated with preeclampsia, fetal growth restriction, medically indicated preterm birth, and stillbirth in some cohorts. The association is often stronger when inhibin A is markedly elevated or combined with abnormal AFP, hCG, PAPP-A, placental growth factor, blood pressure, or uterine-artery Doppler.
Association does not equal diagnosis. Most patients with a mildly elevated marker do not develop a severe placental complication, and many patients who develop preeclampsia had unremarkable inhibin A. Clinical usefulness depends on whether the result changes surveillance beyond established risk factors.
The test has further limitations:
- reference medians and correction factors vary by laboratory;
- inaccurate dating can distort every marker;
- twin and vanishing-twin pregnancies are harder to interpret;
- the screen estimates a limited set of fetal conditions;
- predictive value changes with maternal age and population prevalence;
- a low-risk result leaves residual risk;
- a high-risk result requires confirmation before diagnosis.
For placental health, clinicians rely on blood pressure and symptoms, fetal growth, amniotic fluid, Doppler studies, and fetal surveillance when indicated. Contact the prenatal team promptly for severe headache, visual disturbance, right-upper-abdominal pain, sudden swelling, vaginal bleeding, fluid leakage, contractions, or reduced fetal movement. These symptoms require direct assessment rather than repeat inhibin A testing.
When reading a result, focus on four items: the corrected MoM, the complete marker pattern, the final condition-specific probability, and the follow-up recommendation. The inhibin A number becomes meaningful only inside that larger framework.
An inhibin A result can also attract attention after the chromosome-risk calculation is low. Higher second-trimester values have been associated in population studies with preeclampsia, fetal growth restriction, preterm birth, and stillbirth, particularly when elevations are substantial or other markers are abnormal. Association does not mean that inhibin A predicts which individual pregnancy will develop a complication.
The response to an isolated elevation varies. The obstetric team may review blood-pressure risk factors, the anatomy scan, placental appearance, and other serum markers. Some practices consider later growth ultrasound or surveillance when the value is markedly high, while others base monitoring on the complete clinical profile. Inhibin A alone is not a diagnostic test for placental insufficiency and is not a treatment target.
Aspirin decisions should not be made solely from an analyte value without considering guideline-defined preeclampsia risk factors and gestational timing. Likewise, an elevated result does not justify early delivery in the absence of maternal or fetal indications. Surveillance, when recommended, is intended to detect clinical changes rather than to normalize the hormone.
For a portal result, confirm whether the number is raw concentration or corrected MoM, whether the gestational age and maternal data were correct, and whether the final trisomy risk crossed the screening cutoff. This prevents a laboratory flag on one marker from being mistaken for a fetal diagnosis.
In multiple gestation, one maternal inhibin A value represents combined placental production and cannot assign risk to a particular fetus. Screening software must use a twin-specific model, and the result may be less accurate than in a singleton pregnancy. A vanishing twin can also leave placental tissue that alters markers. These situations should be disclosed before the calculation and reviewed before acting on a positive result.
A repeat inhibin A level later in pregnancy is not a standard way to show that risk has improved. Follow-up uses ultrasound, maternal assessment, and established fetal surveillance rather than trying to normalize the marker.
References
- Prenatal Genetic Screening 2025 (Review)
- Biochemical Screening for Fetal Trisomy 21: Pathophysiology of Maternal Serum Markers and Involvement of the Placenta 2023 (Review)
- Endocrinology of Pregnancy 2021 (Review)
- Alpha-Fetoprotein Analysis 2024 (Review)
- ANTEPARTUM CARE 2025 (Clinical education review)
Disclaimer
This article offers general education about inhibin A and second-trimester screening. An individual result must be interpreted from the complete quad-screen report, laboratory method, dating, ultrasound findings, and medical history by an obstetric clinician or genetic counselor. Seek prompt care for reduced fetal movement, bleeding, severe headache, visual symptoms, or significant abdominal pain.
